Allergan announces it has reached a settlement with two plaintiffs in Ohio in the multi-district federal litigation over opioids.
Rova-T failed to show a survival benefit for patients when compared with a placebo.
The long-term technical view of GSK is very bullish.
The company will be the exclusive U.S. distributor of fungal disease medication Posaconazole delayed-release tablets.
Purdue Pharma is offering to settle more than 2,000 lawsuits related to the opioid crisis, NBC reports.
No company is safe from the litigation risk tied to the drug epidemic, but Johnson & Johnson may be one of the few guaranteed to survive.
By failing to settle like Purdue Pharma, JNJ is taking a risky gamble that could open itself up to many more state court battles and penalties.
Wall Street expects the healthcare giant can take the jolt from the penalty delivered by an Oklahoma judge in the state's opioid case against J&J.
I am not focused on today's price movement of the stock but the pattern from the end of 2017.
Sign up to get started or log in to see your watchlist.
Enter a symbol above to add it to your watchlist.
A confirmation email has been sent to the address provided during registration. Please click on the appropriate link to confirm your email address.